Our clients’ passion to create positive change is what drives us. We recently helped support the Biosimilars Forum’s visit to Capitol Hill to thank industry champions that are helping to increase access to lower-cost medications for patients that need them. Signal’s team of Scott Lusk, Ari Neugeboren, and William Burdulis help the Forum and its members highlight the importance of biosimilar access.
Last week, the Biosimilars Forum and its member companies met with lawmakers on Capitol Hill to thank them for their leadership on biosimilars and discuss the importance of increasing access to these lower-cost medicines. Biosimilars are a bipartisan solution to lower drug costs for millions of Americans, and the work being done by policymakers to increase uptake is imperative to unlocking their cost-savings potential. We look forward to our continued work with both sides of the aisle and the Administration to realize the promise of biosimilars. #biosimilars Juliana "Julie" Reed, Len Arsenault, Jon Martin, Brian McCormick, Tom Shea, Dominick Oliverio, Julian Malasi, Joshua Salsi, Seemin Pasha, Nicholas Schemmel, Nimish Shah
President at Signal Group
3moAmazing work by the Signal team members!